← Research
Nov 2022 Phase 2
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin GM, Aaronson ST, Alvarez O, et al. — University of Oxford / COMPASS Pathways
Published in New England Journal of Medicine
233 patients with treatment-resistant depression across 22 sites in 10 countries received a single 25mg, 10mg, or 1mg (control) dose of COMPASS Pathways' synthetic psilocybin, COMP360. The 25mg group showed significantly greater MADRS reduction than the 1mg group at week 3; about 30% of the 25mg group were in remission.
Read the Full Paper at New England Journal of Medicine